Neuren Pharmaceuticals Ltd has released a press release.
NEU confirms primary endpoints for Phase 3 trial in PMS
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- Neuren initiates development of NNZ-2591 to treat HIE
- Neuren receives DAYBUE sales milestone payment of US$50m
- 2024 results - A$166m comprehensive income for shareholders
- Appendix 4E and 2024 full year accounts
- DAYBUE (trofinetide) 2024 net sales US$348 million
Later from Neuren Pharmaceuticals
- DAYBUE Q1 2025 net sales US$84.6m up 11% from Q1 2024
- AGM Chair Address & CEO Presentation
- US patent allowed for NNZ-2591 to treat Pitt Hopkins
- DAYBUE Q2 2025 net sales US$96.1 million up 14% from Q2 2024
- Neuren adds SYNGAP1-related disorder to NNZ-2591 pipeline
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals